Nanocovax
NNG27
Phase 3 mab completed
Quick answer
Nanocovax for SARS-CoV-2 Infection is a Phase 3 program (mab) at Biotech Pharmaceutical Co., with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Biotech Pharmaceutical Co.,
- Indication
- SARS-CoV-2 Infection
- Phase
- Phase 3
- Modality
- mab
- Status
- completed